WHAT IS CLAIMED IS:

1. An orally administerd composition comprising a therapeutically effective amount of a racemic mixture of a propionic acid derivative, wherein said composition contains from about 50 to about 150 weight percent fumaric acid based upon the weight of the racemic mixture of the propionic acid derivative.

2. The orally administered composition of claim 1 wherein the racemic mixture of a propionic acid derivative is provided as a plurality of coated drug particles wherein the particle coating is selected from the group consisting of polymers and waxes.

3. The orally administered composition of claim 1 wherein the racemic mixture of a propionic acid derivative is provided as a plurality of polymer-coated granules containing active and excipients.

4. The orally administered composition of claim 2 wherein the polymeric coating material is a hydrocolloid; provided that no fumaric acid is incorporated in said hydrocolloid coating on the particles or granules of propionic acid derivative.

5. The orally administered composition of claim 4; provided that no fumaric acid is contained in the propionic acid derivative granules.

6. The orally administered composition of claim 4 wherein the hydrocolloid material is less than about 5 weight percent of the total composition weight.

7. The orally administered composition of claim 1 wherein the level of fumaric acid is from about 5% to about 60% by weight of the total dosage form.

8. The orally administered composition of claim 1 wherein the level of fumaric acid is from about 7% to about 13% by weight of the final dosage form.

9. The orally administered composition of claim 1 wherein the racemic mixture of a propionic acid derivative is ibuprofen.

10. The orally administered composition of claim 1 wherein fumaric acid/racemic mixture of a propionic acid derivative is provided in a tablet.

11. The orally administered composition of claim 1 which is in the form of a chewable dosage form.

12. The orally administered composition of claim 1 which is consumed as a liquid.

13. The orally administered composition of claim 1 which is in the form of a semi-solid.

14. The orally administered composition of claim 1 which is in the form of a suckable solid.

15. A method for reducing the burn sensation of propionic acid derivative compositions comprising:

providing a therapeutically effective amount of a racemic mixture of a propionic acid derivative, which is optionally provided as a granule containing active and excipients and optionally provided with a coating;

providing from about 50 to about 150 weight percent of fumaric acid based upon the weight of propionic acid derivatives in an excipient formulation;

admixing said racemic mixture of a propionic acid derivative and excipient formulation containing said fumaric acid to form a mixture;

provided said coating is substantially free of fumaric acid.

16. The method of claim 15 wherein the racemic mixture of a propionic acid derivative is ibuprofen.

17. The method of claim 15 wherein the fumaric acid and racemic mixture of a propionic acid derivative are admixed in a granulation process.

18. The method of claim 15 wherein the granulation process is conducted with a non-hydrocolloid binder.

19. The method of claim 16 wherein the ibuprofen is granulated with excipients and coated with a hydrocolloid.

20. The method of claim 19 wherein the hydrocolloid coating consists essentially of one or more cellulose derivatives.

21. The method of claim 19 wherein the hydrocolloid is selected from the group consisting of hydroxyethylcellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxymethylcellulose and mixtures thereof.

22. The method of claim 19 wherein the excipients are selected from the group consisting of polyvinylpyrrolidone, sodium starch glycolate and sodium lauryl sulfate, and cellulose derivatives.